Kiniksa Pharmaceuticals International (KNSA) Tax Provisions (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Tax Provisions for 10 years, with the latest figure at $10.1 million in Q1 2026.

• For the quarter ending Q1 2026, Tax Provisions rose 43.6% year-over-year to $10.1 million; the trailing twelve-month figure through Mar 2026 stood at $32.9 million (up 209.48% YoY), and the FY2025 full-year result was $29.9 million, up 324.13% from the prior year.
• Tax Provisions for Q1 2026 stood at $10.1 million, up from $9.1 million in the prior quarter.
• The five-year high for Tax Provisions was $11.0 million in Q4 2023, with the low at -$177.4 million in Q3 2022.
• Historically, Tax Provisions has averaged -$7.2 million across 5 years, with a median of $5.0 million in 2025.
• The largest YoY upside for Tax Provisions was 816.67% in 2022 against a maximum downside of 150203.39% in 2022.
• Kiniksa Pharmaceuticals International's Tax Provisions stood at $2.4 million in 2022, then jumped by 362.23% to $11.0 million in 2023, then sank by 173.55% to -$8.1 million in 2024, then soared by 212.1% to $9.1 million in 2025, then increased by 11.23% to $10.1 million in 2026.
• The last three Tax Provisions figures came in at $10.1 million (Q1 2026), $9.1 million (Q4 2025), and $8.7 million (Q3 2025), per Business Quant data.